Piracetam therapy does not enhance cognitive functioning in children with down syndrome

Area of Science:

• Neuroscience
• Developmental Pediatrics
• Pharmacology

Background:

• Piracetam is frequently administered to enhance cognitive function in children with Down syndrome.
• The efficacy of piracetam for this purpose lacks rigorous scientific evaluation.

Purpose of the Study:

• To assess the effectiveness of piracetam in improving cognitive function in children with Down syndrome.
• To evaluate the safety and side effects of piracetam therapy in this population.

Main Methods:

• A randomized, double-blind, placebo-controlled crossover study design was employed.
• Twenty-five children with Down syndrome (aged 6.5-13 years) participated.
• Cognitive function was assessed using a range of tests, including those for attention, learning, and memory.

Main Results:

• Piracetam therapy did not yield significant improvements in cognitive performance compared to placebo.
• Central nervous system stimulatory effects were observed in 7 children, including aggressiveness, agitation, irritability, sexual arousal, poor sleep, and decreased appetite.

Conclusions:

• Piracetam therapy demonstrated no enhancement of cognition or behavior in children with Down syndrome.
• The study concluded that piracetam is associated with adverse effects in this population.